Although this conclusion failed to be validated in the Impassion130 study due to data permission, we successfully validated the efficacy of the TRG score in other immunotherapy cohorts in metastatic urothelium carcinoma and melanoma treated with anti-PDL1, anti-PD1, and anti-MAGE-A3. Here, MAGEA3 is linked to melanoma.